globalagliatin hydrochloride

DRUG2 trials

Sponsors

Yabao Pharmaceutical Group

Conditions

Healthy VolunteersHyperglycaemia (Diabetic)Type 2 Diabetes Mellitus

Phase 1

The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride

CompletedNCT03171623

Yabao Pharmaceutical GroupHealthy Volunteers, Hyperglycaemia (Diabetic)

Start: 2017-04-05End: 2018-01-09Updated: 2018-01-31

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

CompletedNCT03414892

Yabao Pharmaceutical GroupHyperglycaemia (Diabetic), Type 2 Diabetes Mellitus

Start: 2018-01-03End: 2019-12-01Updated: 2020-01-03

Related Papers

Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study.

2022-01-292 citations

Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study.

2020-10-309 citations